CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO blood type genotyping solution, at the European Federation for Immunogenetics (EFI) Conference 2026.

AlloSeq Nano is an innovation developed by CareDx to deliver high‑resolution HLA genotyping in under three hours with streamlined long‑read library prep workflow, rapid assay turnaround, robust performance, and enhanced resolution.

In early access testing, Alloseq Nano's single-step amplification and prep workflow required approximately 45 minutes of hands‑on time to assay eleven HLA loci plus ABO in a single test. The assay's elegant probe redundancy helps minimize allele dropout, while long-read sequencing reduces phasing ambiguities, enhancing overall performance and accuracy.

AlloSeq Nano expands CareDx's pre‑transplant Lab Products portfolio, alongside AlloSeq Tx and QTYPE®, to support a broader range of laboratory throughput requirements and use cases.

To introduce AlloSeq Nano, CareDx will host a satellite symposium at EFI 2026 on Thursday, April 23, from 13:00–14:00 BST, at the Edinburgh Congress Centre, Sidlaw Auditorium. The symposium will feature scientific and educational discussions related to AlloSeq Nano and CareDx's transplant diagnostics portfolio.

CareDx will also present multiple abstracts at EFI 2026 reflecting scientific engagement across laboratory, clinical, and technical dimensions of transplant diagnostics. Accepted abstracts include presentations featuring AlloSeq cfDNA in kidney and lung transplant settings, as well as a presentation featuring QTYPE®, highlighting rapid ABO genotyping in combination with HLA typing.